BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28331672)

  • 1. Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.
    Kayahan M; İdiz UO; Gucin Z; Erözgen F; Memmi N; Müslümanoğlu M
    J Breast Health; 2014 Oct; 10(4):201-208. PubMed ID: 28331672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
    Ribelles N; Perez-Villa L; Jerez JM; Pajares B; Vicioso L; Jimenez B; de Luque V; Franco L; Gallego E; Marquez A; Alvarez M; Sanchez-Muñoz A; Perez-Rivas L; Alba E
    Breast Cancer Res; 2013; 15(5):R98. PubMed ID: 24148581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.
    Joensuu K; Leidenius M; Kero M; Andersson LC; Horwitz KB; Heikkilä P
    Breast Cancer (Auckl); 2013; 7():23-34. PubMed ID: 23514931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M; Li B; Li Y; Mao X; Yao F; Jin F
    Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.
    Inic Z; Zegarac M; Inic M; Markovic I; Kozomara Z; Djurisic I; Inic I; Pupic G; Jancic S
    Clin Med Insights Oncol; 2014; 8():107-11. PubMed ID: 25249766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
    Verma S; Bal A; Joshi K; Arora S; Singh G
    APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer.
    Husni Cangara M; Miskad UA; Masadah R; Nelwan BJ; Wahid S
    Breast Dis; 2021; 40(S1):S27-S31. PubMed ID: 34057115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer recurrence according to molecular subtype.
    Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
    Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers.
    San TH; Fujisawa M; Fushimi S; Soe L; Min NW; Yoshimura T; Ohara T; Yee MM; Oda S; Matsukawa A
    Asian Pac J Cancer Prev; 2017 Jun; 18(6):1617-1621. PubMed ID: 28670879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.
    Qi JP; Yang YL; Zhu H; Wang J; Jia Y; Liu N; Song YJ; Zan LK; Zhang X; Zhou M; Gu YH; Liu T; Hicks DG; Tang P
    Breast Cancer (Auckl); 2012; 6():1-8. PubMed ID: 22259247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.